Skip to main content

Table 1 Medications taken by OA patients (n = 39), by all RA patients (n = 79) and by RA patients in whom insulin sensitivity was determined (n = 39)

From: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis

Medication

OA (n = 39)

RA (n = 79)

RA (n = 39)

Antihypertensives

10 (26)

18 (23)

8 (21)

Estrogen

6 (15)

6 (8)

2 (5)

NSAID

14 (36)

33 (42)

17 (44)

Low efficacy opioids

3 (8)

5 (6)

2 (5)

Paracetamol

3 (8)

4 (5)

3 (8)

Thyroxine

2 (5)

2 (3)

0 (0)

Glucosamine

2 (5)

3 (4)

0 (0)

Omeprazole

1 (3)

0 (0)

0 (0)

DMARD

0 (0)

42 (53)*

19 (49)

Prednisone

0 (0)

10 (13)**

6 (15)

Amitryptiline

0 (0)

2 (3)

0 (0)

Zopiclone

0 (0)

3 (4)

0 (0)

Metformin

0 (0)

1 (1)

0 (0)

Gliclazide

0 (0)

3 (4)

2 (5)

Insulin

0 (0)

1 (1)

0 (0)

Fluoxetine

0 (0)

1 (1)

1 (3)

Clonazepam

0 (0)

3 (4)

0 (0)

  1. Data presented as n (%). NSAID, nonsteroidal anti-inflammatory agents; DMARD, disease-modifying agents. * Agents were methotrexate (n = 37), chloroquine (n = 17), minocyclin (n = 6), sulphasalazine (n = 4), azathioprine (n = 4), and myocrysin (n = 2). ** Median dose was 5 mg daily (range, 3–20 mg).